Zevra Therapeutics (ZVRA) CMO awarded equity and sells 4,533 shares

Rhea-AI Filing Summary

Zevra Therapeutics’ Chief Medical Officer, Adrian W. Quartel, reported several equity transactions. On January 29, 2026, he received 37,500 restricted stock units (RSUs), each representing one share of common stock, and a stock option for 75,000 shares at an exercise price of $8.86.

The new RSUs will vest one third on January 29, 2027, with the remaining two thirds vesting in equal annual installments, subject to continued service. The stock option vests in four equal annual installments beginning on the first anniversary of the grant date, also subject to continued service.

On January 30, 2026, 11,333 RSUs vested and settled into common shares, and Quartel sold 4,533 shares at a weighted average price of $8.8321 under a Rule 10b5‑1(c) trading plan adopted on March 26, 2025, leaving 9,723 common shares held directly and 22,667 RSUs outstanding.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Quartel Adrian W

(Last) (First) (Middle)

C/O ZEVRA THERAPEUTICS, INC.

1180 CELEBRATION BOULEVARD, SUITE 103

(Street)

CELEBRATION FL 34747

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ZEVRA THERAPEUTICS, INC. [ ZVRA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Medical Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/29/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/30/2026		M		11,333	A	(1)	14,256	D
Common Stock	01/30/2026		S(2)		4,533	D	$8.8321(3)	9,723	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Unit	(1)	01/29/2026		A		37,500		(4)	(4)	Common Stock	37,500	$0	37,500	D
Stock Option (right to buy)	$8.86	01/29/2026		A		75,000		(5)	01/28/2036	Common Stock	75,000	$0	75,000	D
Restricted Stock Unit	(1)	01/30/2026		M			11,333	(6)	(6)	Common Stock	11,333	$0	22,667	D

Explanation of Responses:

1. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.

2. Adoption date of referenced 10b5-1(c) plan is: 3/26/2025.

3. This transaction was executed in multiple trades at prices ranging from $8.62 to $9.04. The price reported reflects the weighted average sale price. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer or any security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected.

4. The restricted stock units will vest and settle as to one third of the restricted stock units on January 29, 2027, and the remaining two thirds of the restricted stock units will vest and settle in equal annual installments thereafter, subject in each case to the Reporting Person's continued service through such vesting date.

5. Grant to the Reporting Person of a stock option under the Issuer's Amended and Restated 2014 Equity Incentive Plan. The option will vest and become exercisable in four equal annual installments beginning on the first anniversary of the grant date, subject to the Reporting Person's continued service on such vesting date.

6. One third of the restricted stock units vested and settled on January 30, 2026. The remaining two thirds of the restricted stock units will vest and settle in equal annual installment thereafter, subject in each case to the Reporting Person's continued service through such vesting date.

Remarks:

	/s/ Timothy J. Sangiovanni, Attorney-in-Fact for Adrian W. Quartel	02/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did Zevra Therapeutics (ZVRA) report for its CMO?

Adrian W. Quartel, Zevra’s CMO, reported grants of 37,500 restricted stock units and a 75,000-share stock option, plus the vesting of 11,333 RSUs and the sale of 4,533 common shares at a weighted average price of $8.8321 under a 10b5-1 plan.

How many Zevra Therapeutics (ZVRA) shares did the CMO sell and at what price?

Quartel sold 4,533 shares of Zevra common stock at a weighted average price of $8.8321 per share. The sale occurred on January 30, 2026, through multiple trades within a price range from $8.62 to $9.04, as disclosed in the Form 4 footnote.

What equity awards did the Zevra Therapeutics (ZVRA) CMO receive on January 29, 2026?

On January 29, 2026, Quartel received 37,500 restricted stock units and a stock option covering 75,000 Zevra common shares at an exercise price of $8.86. Both awards vest over multiple years, contingent on his continued service with the company through each vesting date.

What is the vesting schedule for the new Zevra Therapeutics (ZVRA) RSU grant?

The 37,500 RSUs granted to Quartel vest one third on January 29, 2027. The remaining two thirds vest and settle in equal annual installments thereafter, with each tranche dependent on his continued service through the applicable vesting date, according to the filing’s footnote.

How does the Zevra Therapeutics (ZVRA) CMO’s stock option vest?

The 75,000-share stock option granted to Quartel vests in four equal annual installments. Vesting begins on the first anniversary of the January 29, 2026 grant date, and each installment requires his continued service on the relevant vesting date under the company’s equity plan.

What trading plan covered the Zevra Therapeutics (ZVRA) CMO’s share sale?

The 4,533-share sale on January 30, 2026, was executed under a Rule 10b5-1(c) trading plan. The filing states that this plan was adopted on March 26, 2025, providing a pre-arranged framework for selling shares according to predetermined instructions.